274 related articles for article (PubMed ID: 15598783)
1. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
[TBL] [Abstract][Full Text] [Related]
2. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients.
Bau DT; Tsai MH; Lo YL; Hsu CM; Tsai Y; Lee CC; Tsai FJ
Anticancer Res; 2007; 27(3B):1559-64. PubMed ID: 17595776
[TBL] [Abstract][Full Text] [Related]
3. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer.
Roh JW; Kim JW; Park NH; Song YS; Park IA; Park SY; Kang SB; Lee HP
Gynecol Oncol; 2004 May; 93(2):499-505. PubMed ID: 15099969
[TBL] [Abstract][Full Text] [Related]
4. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan.
Wu MT; Chen MC; Wu DC
Cancer Lett; 2004 Mar; 205(1):61-8. PubMed ID: 15036662
[TBL] [Abstract][Full Text] [Related]
5. Association of XPD polymorphisms with prostate cancer in Taiwanese patients.
Bau DT; Wu HC; Chiu CF; Lin CC; Hsu CM; Wang CL; Wang RF; Tsai FJ
Anticancer Res; 2007; 27(4C):2893-6. PubMed ID: 17695467
[TBL] [Abstract][Full Text] [Related]
6. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
[TBL] [Abstract][Full Text] [Related]
7. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
10. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis.
Wang YC; Chen CY; Chen SK; Chang YY; Lin P
Clin Cancer Res; 1999 Jan; 5(1):129-34. PubMed ID: 9918210
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women.
Lee SA; Kim JW; Roh JW; Choi JY; Lee KM; Yoo KY; Song YS; Kang D
Gynecol Oncol; 2004 Apr; 93(1):14-8. PubMed ID: 15047208
[TBL] [Abstract][Full Text] [Related]
12. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 and CDKN1A genotypes with endometriosis.
Ying TH; Tseng CJ; Tsai SJ; Hsieh SC; Lee HZ; Hsieh YH; Bau DT
Anticancer Res; 2011 Dec; 31(12):4301-6. PubMed ID: 22199295
[TBL] [Abstract][Full Text] [Related]
15. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
Saudi Med J; 2004 Apr; 25(4):447-51. PubMed ID: 15083213
[TBL] [Abstract][Full Text] [Related]
17. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population.
Huang SP; Chou YH; Wayne Chang WS; Wu MT; Chen YY; Yu CC; Wu TT; Lee YH; Huang JK; Wu WJ; Huang CH
Cancer Lett; 2004 Apr; 207(1):69-77. PubMed ID: 15050735
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ
Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840
[TBL] [Abstract][Full Text] [Related]
19. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
